Windy City Media Group Frontpage News


home search facebook twitter join
Gay News Sponsor Windy City Times 2023-09-06



HIV/AIDS groups to FDA, Gilead Sciences: Do not delay HIV prevention for gay, bi men, trans women
From a news release

This article shared 2198 times since Tue Oct 18, 2011
facebook twitter google +1 reddit email

NEW YORK, Oct. 18, 2011 /PRNewswire-USNewswire/ -- Thirteen prominent U.S. HIV/AIDS organizations have issued an open letter to the U.S. Food and Drug Administration and Gilead Sciences calling for prompt regulatory review of pre-exposure prophylaxis (PrEP) for HIV prevention in gay and bisexual men and transgender women (men who have sex with men, or MSM). The letter urges FDA and Gilead to start the review process that could allow safe and appropriate approved PrEP use as a public health intervention, and not to delay review because of distinct questions about the safety and efficacy of PrEP in heterosexual populations. The letter is available online at:

Pre-exposure prophylaxis, or PrEP, is a new HIV prevention method in which an uninfected person takes a daily HIV medication to reduce HIV infection risk. Data from an international study released in November, 2010 called iPrEx found that men and transgender women who have sex with men who received a daily single-tablet dose of the HIV drugs tenofovir and emtricitabine along with condoms and safe sex counseling had an average of 42% fewer HIV infections than those who received condoms and counseling alone.

Advocates assert that the need for new HIV prevention strategies for MSM is urgent. The U.S. Centers for Disease Control (CDC) estimates that MSM account for more than half of all new HIV infections in the United States. CDC logged an estimated 34% increase in HIV infections in young gay men between 2006 and 2009, and a 48% HIV increase among young black/African American gay men over the same period.

"We desperately need ew strategies and tools to reduce the rapidly increasing rates of HIV infection in black gay and bisexual men," said Phill Wilson, executive director of the Black AIDS Institute. "We've had evidence of PrEP's effectiveness in MSM for almost a year now. It's time to use every tool at our disposal to reduce the 50,000 new HIV infections that occur each year in this country. Prompt FDA review will help ensure that appropriate guidelines for PrEP use are established that can reduce HIV infections and safeguard public health."

Data on PrEP in heterosexuals raise important but unique questions that may require further study. Two major trials in Africa found that PrEP reduces HIV infection risk in heterosexual men and women substantially. But two other studies present conflicting information about how PrEP works in heterosexuals. Critical and necessary efforts to understand how PrEP interacts with hormonal contraception, or how PrEP may impact pregnancy, however, should not delay access to a potentially lifesaving form of HIV prevention for MSM.

Before the results of the heterosexual PrEP studies were announced, the FDA and Gilead Sciences, the maker of the drugs, were reported to be ready to move quickly to consider approval of PrEP for those MSM who could benefit from the approach. Recent signs indicate, however, that FDA review of PrEP for this population may not start until the agency acquires more data on PrEP among heterosexuals — despite the urgent need for new HIV prevention strategies for MSM, and the fact that PrEP data in MSM were announced nearly one year ago.

"The FDA and Gilead Sciences should move quickly to ensure a thorough review of PrEP for MSM now, while they both work simultaneously and swiftly to thoroughly address questions and concerns about PrEP among heterosexual populations," said Mitchell Warren, executive director of AVAC "Prompt FDA review of PrEP in MSM is the right thing to do for public health. In the midst of a growing HIV epidemic, HIV prevention delayed is HIV prevention denied."

October 18, 2011

An Open Letter to the U.S. Food and Drug Administration and Gilead Sciences

RE: Timing the Review and Approval of Pre-exposure Prophylaxis for HIV Prevention

We, the undersigned, are non-profit organizations and coalitions who support the development of and access to new safe and effective HIV prevention options in the United States and globally. Data from multiple clinical trials in different populations showing that antiretroviral drugs for HIV treatment can also prevent HIV infection have accumulated to the point where FDA approval decisions could be made for this intervention. The approval issues for the different populations are not identical. For the reasons outlined below, we urge the FDA and Gilead Sciences to reconsider plans to combine the approval for a prevention indication for both men who have sex with men, including transgender populations (MSM) and heterosexuals into a single filing. The combination could unnecessarily delay approval for MSM, the group at greatest risk of HIV infection in the United States.

FDA has a duty to move forward on beneficial products by setting out best terms of use, and, by law, to "promote the public health by promptly and efficiently reviewing clinical research and taking appropriate action on the marketing of regulated products in a timely manner." This duty is what's in question today.

Results from three large clinical trials show that oral pre-exposure prophylaxis (oral PrEP) has the potential to prevent new HIV infections. Last year the iPrEx trial found that daily TDF/FTC (marketed as Truvada by Gilead) along with standard prevention reduced HIV infection risk by 42% in at-risk gay/bisexual men and transgender women who have sex with men (MSM).

The results preceded release of important infection data for MSM in the U.S. The U.S. Centers for Disease Control (CDC) estimates that MSM account for more than half of all new HIV infections in the U. S. For many MSM the HIV risk is growing. CDC found an estimated 34% increase in HIV infections in young MSM between 2006 and 2009, and a 48% increase in HIV among young black/African American MSM over the same period. MSM represent a population with demonstrable need for effective prevention tools.

Two additional trials have shown that oral TDF/FTC (or TDF alone as in one of the trials) as PrEP also reduces HIV infection risk by 62-73% in at-risk heterosexual men and women. But a fourth study of oral TDF/FTC as PrEP, which was conducted in a population of heterosexual women, was stopped before its anticipated end date after an interim data review found equal numbers of infections in the experimental and placebo arms. More recently, the oversight board of an ongoing PrEP trial comparing oral TDF alone to oral TDF/FTC and a gel containing TDF recommended discontinuing the use of oral TDF alone in a single arm of the study. That approach was deemed unable to show efficacy in the population of heterosexual women being studied. The other arms of the study continue to evaluate the other PrEP modalities. We do not yet know why this pattern emerged in these trials. Nevertheless, combined data show oral PrEP may be a vitally important prevention tool for some heterosexual populations.

Separate safety and effectiveness questions in data collected in heterosexual groups may unduly lengthen FDA review for MSM if the two approvals are bundled together. In addition to clarity surrounding the one trial that was stopped, FDA may have questions about:

Offering oral PrEP to women who use hormonal contraceptives concurrently;

Balancing risks to unborn children exposed to drugs in the absence of a known risk of exposure to HIV from an uninfected pregnant mother;

The basis of using two-drug combinations vs single drugs in heterosexual populations.

The US DHHS perinatal guidelines for HIV recently withheld recommendations for oral PrEP based on these concerns. If approval for both MSM and heterosexuals is bundled together, it may take many months to answer the questions affecting one group more than the other.

Harms result when the benefits of FDA approval are delayed for a safe and effective intervention:

Patients do not have the benefit of the safety and control measures that come with proper labeling, study- and FDA-regulated risk management;

FDA regulatory requirements are not able to be integrated with or to facilitate other efforts to demonstrate real world effectiveness in a cohesive organized manner;

FDA approval spurs insurance coverage from private and public sources needed to secure equitable access for disadvantaged populations;

The drug manufacturer will be restricted from communicating important data to clinics because of restraints on unauthorized marketing;

While PrEP should only be given to those who can truly benefit, a delayed approval means many of them will simply not get it at all. Whichever infections could have been averted will unfortunately occur.

These harms should not be imposed on either MSM or heterosexuals. FDA's duty also requires the Agency to safeguard patients from uncertainty, and today, unfortunately, that uncertainty possibly weighs more heavily with one group more than the other. We must shore up that uncertainty promptly but not delay access to risk-reducing tools for MSM sooner if we can. Approval delayed, like justice, is approval denied.

FDA approval also influences the availability of PrEP in other countries hardest-hit by HIV/AIDS that look to the FDA for assurance that a new therapy is safe and effective. The largest international program for HIV treatment and prevention in developing countries, PEPFAR, considers FDA approval an important step in providing programming/access to PrEP.

Before the results of heterosexual PrEP studies were announced, the FDA and Gilead were reported to be ready to move forward on a review of PrEP for MSM. Now it looks like action on PrEP for MSM may take longer. Even six months of further delay could result in many preventable new HIV infections.

The FDA and Gilead should move quickly to ensure a thorough review of PrEP for MSM. It's time. We also urge no delay to clear up data that will help heterosexual populations in need. Useful interventions often go through sequential approvals as was the case for Gardasil to prevent HPV related cancers and lesions in young women and men. Oral PrEP is not a magic pill but it adds to the available arsenal we have to prevent HIV.

Sincerely yours,

AIDS Action Committee of Massachusetts

AIDS Foundation of Chicago

AIDS Research Consortium of Atlanta

AIDS United


Black AIDS Institute

Fenway Health


Harlem United

International Rectal Microbicides Advocates

National Minority AIDS Council

Project Inform

San Francisco AIDS Foundation

This article shared 2198 times since Tue Oct 18, 2011
facebook twitter google +1 reddit email

Out and Aging
Presented By


Gay News

AIDS Run & Walk Chicago: moving against HIV/AIDS 2023-10-04
- AIDS Run & Walk Chicago photos by Vern Hester. ...

Gay News

AIDS Run & Walk Chicago 2023 to draw thousands to Soldier Field on Sept. 30 2023-09-09
- The AIDS Run & Walk Chicago returns to Chicago's Soldier Field on Saturday, Sept. 30 to help create equity and justice across Chicagoland and raise awareness and funds for individuals who are living with or vulnerable ...

Gay News

Chicago Dancers United raises more than $365K at Dance for Life 2023-08-29
- Chicago Dancers United (CDU)—which supports the health and wellness of Chicago's professional dance community—welcomed 1,600 people to the 32nd annual Dance for Life on Aug. 19 at Auditorium Theatre, per ...

Gay News

New guidelines increase HIV antiretroviral options 2023-08-26
- The U.S. Preventive Services Task Force (USPSTF) is expanding its recommendation for HIV antiretrovirals because more options are available on the market, according to MedScape. The guidance, published Aug. 22 in JAMA, updates the group's prev ...

Gay News

'Show up, Show out!' 32nd Annual AIDS Run & Walk Chicago on Sept. 30 2023-08-07
--From a press release - (Chicago, IL) Registration is now open for the 32nd annual AIDS Run & Walk Chicago (ARWC) presented by AIDS Foundation Chicago (AFC) on Saturday, September 30 at Soldier Field. "Show up, Show Out" is this year's ...

Gay News

Chicago House indulges in Champagne Wrapture 2023-08-06
- Chicago House's annual fundraiser, Champagne Wrapture, returned to the Windy City the evening of Aug. 3. The event was held at 600 N. Fairbanks Court on the rooftop deck and featured a silent auction, free-flowing champagne, ...

Gay News

LGBTQ+ cycling club builds both community and awareness 2023-08-01
By Charlie Kolodziej - For the second summer in a row, Cruise Chi, Chicago's new LGBTQ+ cycling club, has been fostering a sense of community while supporting queer- and trans-advocacy. The group, led by co-founders Alton Deon and Shai Garcia, ...

Gay News

Gilead prevails in HIV antitrust suit brought by consumers 2023-07-01
- On June 30, pharmaceutical giant Gilead Sciences triumphed over consumers in a $3.6-billion class-action suit that claimed the company deliberately manipulated the market in order to profit off of its expensive HIV treatment drugs, Courthouse News ...

Gay News

Lakeside Pride Music Ensembles first out HIV+ board chair works to grow visibility 2023-06-28
--From a press release - Chicago, Illinois — Lakeside Pride Music Ensembles, Chicago's premiere music groups for the LGBTQ+ community members and allies, is currently under the direction of its first out HIV+ board chair, Brandon Strawn. Strawn has been a ...

Gay News

PASSAGES Artist Stash Kybartas 2023-06-17
- Stashu Kybartas, a video artist who also worked in installation and performance art, passed away May 17 at his home in Chicago. Robert Colucci, his husband of 48 years, was with him at the time of ...

Gay News

NATIONAL Google Doodle, drag laureate, Nebraska bill, NYC AIDS Walk 2023-05-26
- D.C. poet/activist/journalist Ivy Young passed away at age 75, per a press release. Among other things, Young worked at Chicago's VISTA; the Center for Black Education and Drum and Spear Book Store in D.C.; the ...

Gay News

TaskForce Chicago's ED talks organization, AIDS stigma and queerness 2023-05-25
- Among the many organizations helping Chicago youths is TaskForce Prevention & Community Services. The West Side-based organization helps hundreds of youths by being committed to addressing the HIV/STI-related needs of ...

Gay News

HB 1286 would allow gender-inclusive multi-occupancy restrooms, Chicago groups respond 2023-05-19
--From a press release - Statement from AIDS Foundation Chicago, Equality Illinois, and Pride Action Tank regarding HB 1286 to allow gender-inclusive multi-occupancy restrooms: We applaud the Illinois Senate for passing HB 1286 and urge the Illinois House to act expeditiously ...

Gay News

Belting for Life returns for an 8th edition 2023-05-18
- On May 15, Jeff Award-winning director and activist Christopher Pazdernik celebrated his birthday with the eighth edition of Belting for Life, his annual Chicago-style theatrical concert and fundraiser for AIDS ...

Gay News

Chicago House welcomes spring with 'Secret Garden' event 2023-05-12
- On May 7, Chicago House presented its annual spring fashion brunch, this year titled The Secret Garden, in the Winter Green Ballroom of the Harold Washington Library. The annual event, which some now regard as the ...


Copyright © 2023 Windy City Media Group. All rights reserved.
Reprint by permission only. PDFs for back issues are downloadable from
our online archives.

Return postage must accompany all manuscripts, drawings, and
photographs submitted if they are to be returned, and no
responsibility may be assumed for unsolicited materials.

All rights to letters, art and photos sent to Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago
Gay and Lesbian News and Feature Publication) will be treated
as unconditionally assigned for publication purposes and as such,
subject to editing and comment. The opinions expressed by the
columnists, cartoonists, letter writers, and commentators are
their own and do not necessarily reflect the position of Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago Gay,
Lesbian, Bisexual and Transgender News and Feature Publication).

The appearance of a name, image or photo of a person or group in
Nightspots (Chicago GLBT Nightlife News) and Windy City Times
(a Chicago Gay, Lesbian, Bisexual and Transgender News and Feature
Publication) does not indicate the sexual orientation of such
individuals or groups. While we encourage readers to support the
advertisers who make this newspaper possible, Nightspots (Chicago
GLBT Nightlife News) and Windy City Times (a Chicago Gay, Lesbian
News and Feature Publication) cannot accept responsibility for
any advertising claims or promotions.






About WCMG      Contact Us      Online Front  Page      Windy City  Times      Nightspots
Identity      BLACKlines      En La Vida      Archives      Advanced Search     
Windy City Queercast      Queercast Archives     
Press  Releases      Join WCMG  Email List      Email Blast      Blogs     
Upcoming Events      Todays Events      Ongoing Events      Bar Guide      Community Groups      In Memoriam     
Privacy Policy     

Windy City Media Group publishes Windy City Times,
The Bi-Weekly Voice of the Gay, Lesbian, Bisexual and Trans Community.
5315 N. Clark St. #192, Chicago, IL 60640-2113 • PH (773) 871-7610 • FAX (773) 871-7609.